Abstract
Objective: To determine whether higher fish intake is associated with a reduced risk of multiple sclerosis (MS) and, if so, whether single nucleotide polymorphisms (SNPs) in fatty acid biosynthesis genes are also associated with MS risk.
Background: Marine diet is the best source of omega-3 polyunsaturated fatty acids (PUFAs). High fish intake has been associated with a lower risk of MS but whether this is due to PUFAs or other nutrients is unclear. SNPs in the fatty acid desaturase (FADS) gene cluster that modulate fatty acid levels have been associated with cognition, cardiovascular disease and inflammation. Whether they are associated with MS is unknown.
Design/Methods: We examined the association of fish consumption, 13 tag SNPs in FADS1, FADS2 and ELOV2 with risk of MS in 1153 individuals from the MS Sunshine Study, a multi-ethnic matched case-control study of incident MS or its precursor, clinically isolated syndrome (CIS), recruited from Kaiser Permanente Southern California. High fish intake was defined as consuming fish ≥1/week or 1–3 servings/month + fish oil supplements. Logistic regression models were utilized and adjusted for age, sex, smoking, genetic ancestry and HLADRB1*15:01.
Results: High fish intake was associated with a 45% reduced risk of MS/CIS (adjusted OR=0.55; 95%CI 0.40–0.75; p=0.0002) compared with consuming fish <1/month and no supplements. Two tag SNPs, rs174611 and rs174618, in FADS2 were independently associated with a lower risk of MS even after accounting for high fish intake (adjusted ORs 0.66, 0.64, p=0.007, 0.016, respectively).
Conclusions: These analyses support a protective role of fish consumption and PUFA biosynthesis on MS risk. These findings suggest that omega-3 fatty acids may play an important role in reducing MS risk. Future studies to replicate our findings and determine whether this is mediated by the anti-inflammatory, metabolic and/or neurological functions of PUFAs are needed.
Study Supported by: The National Institute of Neurological Disorders and Stroke (NINDS, 1R01NS075308 PI: Langer-Gould)
Disclosure: Dr. Langer-Gould has nothing to disclose. Dr. Black has nothing to disclose. Dr. Wu has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Gonzales has nothing to disclose. Dr. Barcellos has nothing to disclose. Dr. Xiang has nothing to disclose. Dr. Lucas has nothing to disclose.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan